Table 4.
Reasons for discordance between the non–small cell lung cancer line-of-therapy algorithm and blinded chart review: numbers of cases.a
| Reason for discordance | Training cohort (n=350) | Test cohort (n=150) | ||||||||||||||
|
|
Prerefinement | Postrefinement | n (%) | N | ||||||||||||
|
|
n (%) | N | n (%) | N |
|
|
||||||||||
| Simple cases, total discordance | 16 (9.0) | 178 | 8 (4.5) | 178 | 0 (0) | 76 | ||||||||||
|
|
Gap-in-therapy window length | 9 (56) | 16 | 3 (38) | 8 |
|
|
|||||||||
|
|
28-day line regimen window | 3 (19) | 16 | 3 (38) | 8 |
|
|
|||||||||
|
|
Line name disagreement | 3 (19) | 16 | 1 (13) | 8 |
|
|
|||||||||
|
|
Other | 1 (6) | 6 | 1 (13) | 8 |
|
|
|||||||||
| Complex cases, total discordance | 68 (39.5) | 172 | 62 (36) | 172 | 37 (50.0) | 76 | ||||||||||
|
|
Dropped drugs | 22 (32) | 68 | 24 (39) | 62 | 17 (46) | 37 | |||||||||
|
|
Maintenance therapy classification | 14 (21) | 68 | 13 (21) | 62 | 8 (22) | 37 | |||||||||
|
|
28-day line regimen window | 12 (18) | 68 | 12 (19) | 62 | 6 (16) | 37 | |||||||||
|
|
Gap-in-therapy window length | 9 (13) | 68 | 4 (6) | 62 | 2 (5) | 37 | |||||||||
|
|
Other | 11 (16) | 68 | 9 (15) | 62 | 4 (11) | 37 | |||||||||
aPercentages may not add up to 100 because of rounding.